Siegfried Group has acquired Hameln Pharma in Germany, for CHF 60 million. Hameln Pharma, consisting of Hameln Pharmaceuticals GmbH and Hameln RDS GmbH, develops and produces sterile liquid pharmaceutical products for international companies, expanding Siegfried’s sterile filling segment.   The Hameln Group, and its remaining subsidiaries, plans to focus on its business activities with its own brand of injectable pharmaceutical finished products. The R&D site in Slovakia will also remain in ...